Lexaria agrees to warrant inducement for approximately $5.9 million in gross proceeds

Lexaria Bioscience Corp. (Nasdaq: LEXX) agreed on September 7, 2026 to let holders of older warrants exercise them immediately at a reduced price. The Form 8-K describes inducement letters dated that day covering 453,969 shares of common stock. The company's press release of September 8 puts the gross proceeds at about $5.9 million, before placement agent fees and expenses. The closing is expected on or about September 9, 2026, subject to customary conditions.

The warrants being exercised

The warrants were issued in four tranches. They were dated February 16, 2024, with an original exercise price of $32.78 a share; October 16, 2024, at $45.90; September 29, 2025, at $20.55; and December 16, 2025, at $17.85. The new price of $12.92 is below all four original prices. Holders who exercise now pay less per share than the original terms required, and the company receives less cash per share as a result.

The shares underlying the old warrants were already registered under four registration statements on Form S-1 and Form S-3, which the 8-K lists by file number. The company says it expects to use the net proceeds for working capital and general corporate purposes.

What holders receive in return

For the cash exercise, Lexaria will issue new unregistered Series A warrants and short-term Series B warrants. Each series covers up to 453,969 shares, the same number as the exercised warrants. Both carry an exercise price of $12.67 a share, slightly below the $12.92 paid in the exercise. The Series A warrants run five years and the Series B warrants run eighteen months, each from the effective date of a resale registration statement.

That structure means the company is issuing two new sets of warrants on the same number of shares it is selling today. If the holders use them, the company could issue more shares later at prices close to the current exercise price. The filing does not say how many shares would be outstanding after the closing.

The 8-K also says Lexaria agreed to file a resale registration statement within thirty calendar days of the inducement letters, and to use commercially reasonable efforts to have it declared effective within forty-five calendar days, or sixty days if the SEC conducts a full review. The exercise terms set a beneficial ownership limit of 4.99% of outstanding shares, which may be raised to 9.99% on at least 61 days' notice to the company.

Placement agent and advisers

H.C. Wainwright & Co., LLC is the exclusive placement agent for the offering, according to the press release and the 8-K. The company will pay Wainwright a fee equal to 7% of the gross proceeds from the holders' exercises. It also issued placement agent warrants to purchase up to 15,889 shares at $16.15 a share.

Neither the 8-K nor the press release names another bank, financial adviser or lender, or any counsel to Lexaria or to H.C. Wainwright.

The company's finances

Lexaria's annual report for the fiscal year ended August 31, 2025, filed November 28, 2025, shows revenue of $705,923, up from $464,278 a year earlier. The net loss widened to $11.9 million from $5.8 million. Research and development expense rose to $8.2 million from $2.4 million. Cash used in operations was $10.5 million in fiscal 2025, against $5.0 million in fiscal 2024.

The company reported cash and cash equivalents of $3.5 million at May 31, 2026, in its quarterly report filed July 13, 2026. Short-term investments at that date were $142,103. The gross proceeds from this transaction are less than the $10.5 million of operating cash used in fiscal 2025, and neither the 8-K nor the press release gives the company's cash after the closing.

Chief executive Rich Christopher said the proceeds, together with a $2.6 million tax rebate recently received from the Australian Tax Office, "may be utilized to fund our operations and research and development programs in 2027". That is the company's own view. The 8-K gives no cash runway and no share count after the exercise, and it does not say whether the new Series A and Series B warrants will be exercised.

Report an error

Companies in this story

LEXXLexaria Bioscience Corp.NASDAQ · CanadaOpen the starter desk